Your browser doesn't support javascript.
loading
Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma.
Araki, Hidemori; Tsuzuki, Toyonori; Kimura, Tohru; Tanaka, Kuniaki; Yamada, Shin; Sassa, Naoto; Yoshino, Yasushi; Hattori, Ryohei; Gotoh, Momokazu.
Affiliation
  • Araki H; From the Department of Urology, Toyohashi Municipal Hospital, Toyohashi, Japan;
  • Tsuzuki T; Department of Pathology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan; tsuzuki@nagoya2.jrc.or.jp.
  • Kimura T; Department of Urology, Shakaihoken Chukyo Hospital, Nagoya, Japan;
  • Tanaka K; Department of Urology, Kariya Toyota General Hospital, Kariya, Japan;
  • Yamada S; Department of Urology, Okazaki Municipal Hospital, Okazaki, Japan;
  • Sassa N; Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan; and.
  • Yoshino Y; Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan; and.
  • Hattori R; Department of Urology, Japanese Red Cross Nagoya Daiichi Hospital, Nagoya, Japan.
  • Gotoh M; Department of Urology, Nagoya University Graduate School of Medicine, Nagoya, Japan; and.
Am J Clin Pathol ; 143(4): 492-9, 2015 Apr.
Article in En | MEDLINE | ID: mdl-25780000
ABSTRACT

OBJECTIVES:

To evaluate the predictive value of growth patterns in patients undergoing sorafenib treatment for metastatic clear cell renal cell carcinomas (CCRCCs).

METHODS:

Forty-eight patients were analyzed, each of whom underwent nephrectomy and received sorafenib treatment for metastatic CCRCC. Progression-free survival (PFS) was predicted using pathologic parameters, including pathologic stage, Fuhrman nuclear grade (FNG), the presence of a sarcomatoid component, lymphovascular invasion, tumor necrosis, and growth pattern.

RESULTS:

Three (6%) patients showed partial response, 20 (42%) patients showed stable disease, and 25 (52%) patients showed progressive disease. Univariate analyses demonstrated that FNG, the presence of a sarcomatoid component, tumor necrosis, and growth pattern were significantly associated with PFS. In the multivariate analysis, growth pattern was the only parameter that was significantly and independently predictive of PFS.

CONCLUSIONS:

As a novel histologic prognostic parameter, growth pattern may be useful for predicting response to sorafenib treatment.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylurea Compounds / Carcinoma, Renal Cell / Niacinamide / Kidney Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Am J Clin Pathol Year: 2015 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Phenylurea Compounds / Carcinoma, Renal Cell / Niacinamide / Kidney Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Am J Clin Pathol Year: 2015 Document type: Article